Latest Videos |view all videos
Mayo Clinic researchers help to shine new light on bladder cancer tumors.
Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease
Charanjit S. Rihal, M.D., and Stephen L. Kopecky, M.D., discuss erectile dysfunction and its impact on cardiovascular prognosis and diagnosis.
Robert D. Simari, M.D., and Rajiv Gulati, M.D., Ph.D., discuss the data so far and the ongoing Symplicity-HTN3 trial. Will renal denervation move hypertension into the interventional cardiologists' domain?
Eddie L. Greene, M.D., Horng H. Chen, M.D., and Margaret M. Redfield, M.D., gathered to discuss the design, results and implications of the cardiorenal rescue study in acute decompensated heart failure (CARRESS).
Mayo Clinic has integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to prostate cancer patients.
Matthew K. Tollefson, M.D., provides patients and clinicians with a novel way to predict which cases of prostate cancer, the most commonly diagnosed malignancy in American men, will be aggressive and which ones can be safely monitored with watchful waiting.
A commonly used erectile dysfunction drug, sildenafil, doesn't help patients who have heart failure with preserved ejection fraction, a condition in which the heart's lower chambers are stiff and cannot relax and fill fully between beats.